Reuters logo
BRIEF-EU Medicines Agency recommends approval of Novartis' leukaemia drug
July 21, 2017 / 11:37 AM / 5 months ago

BRIEF-EU Medicines Agency recommends approval of Novartis' leukaemia drug

July 21 (Reuters) - EU Medicines Agency:

* EU Medicines Agency recommendations For July 2017

* EU Medicines Agency recommends approval of Pfizer Inc and Merck KGAA Avelumab drug for cell carcinoma‍​

* EU Medicines Agency recommends approval of Sanofi and Regeneron Dupixent drug for severe eczema

* EU Medicines Agency recommends approval Of Roche Tecentriq drug for drug for bladder and lung cancer‍​

* EU Medicines Agency recommends approval Of Advanced Accelerator Applications Lutathera drug for gastroenteropancreatic neuroendocrine tumours

* EU Medicines Agency recommends against approval of Nektar Therapeutics and Daiichi Sankyo Onzeald drug for breast cancer

* EU Medicines Agency recommends approval of Novartis Rydapt drug for leukaemia Source text - bit.ly/2uhkHOu Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below